WIN Consortium in cancer personalized medicine Email Formats
Hospitals and Health Care • 
Villejuif, Île-de-France, France • 1-10 Employees
WIN Consortium in cancer personalized medicine Email Formats
WIN Consortium in cancer personalized medicine uses 1 email format. The most common is {first initial}.{last name} (e.g., j.doe@winconsortium.org), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@winconsortium.org | 100% |
Key Contact at WIN Consortium in cancer personalized medicine
Catherine Bresson
Director Of Operational Team
Company overview
| Headquarters | 9 rue Guy Môquet, Villejuif, Val de Marne 94800, FR |
| Phone number | +331036401 |
| Website | |
| NAICS | 62 |
| SIC | 873 |
| Keywords | Research, Biotech, Pharma, Biomarkers, Diagnostics, Oncology, Bioinformatics, Proteomics, Genomics, Global Collaboration, Cross-Sector Networking, Personalized Cancer Medicine |
| Founded | 2010 |
| Employees | 1-10 |
| Socials |
About WIN Consortium in cancer personalized medicine
WIN: ACCOMPLISH TOGETHER WHAT ONE CANNOT ACHIEVE ALONE WIN IN NUMBERS: 18 countries over 4 continents 26 academic cancer centers - Access to patients from different populations 5 industries – Access to drugs and technologies 3 cancer patient organizations – The voice of the patients WIN MISSION: Significantly improve survival and quality of life of cancer patients across the world. WIN STRATEGY: (i) Perform proof of concept trials designed to explore novel strategies and tools aiming to: - Increase efficacy of Precision Oncology for advanced cancers and access to patients worldwide - Improve early diagnosis (ii) Share information about state of the art research across the world, the work of WIN members, WIN trials and more generally promoting the adoption of personalized cancer medicine globally through an annual symposium. Visit www.winsymposium.org WIN TRIALS: (i) WINTHER - trial results published in Nature Medicine https://doi.org/10.1038/s41591-019-0424-4 WINTHER heralds a new era for personalized medicine in oncology. WINTHER was the first trial to use transcriptome in addition to DNA investigations. Overall, the trial succeeded in matching personalized therapy to 35% of patients with advanced cancers. Patients with a good performance status and a high degree of matching had a significantly longer median overall survival of 25.8 months versus 4.5 months for others, independently of the number of previous therapies. Assessing RNA is an important adjunct to DNA profiling for determining precision treatments. (ii) SPRING_01 tritherapy trial (avelumab, palbociclib and axitinib) in first line of advanced/metastatic lung cancer. Phase I on going. Trial still enrolling at Avera Cancer Institute, USA, Vall d'Hebron (Spain), UC San Diego Moores Cancer Center, USA, Vall d’ Hebron Institute of Oncology, Spain, Centre Hospitalier de Luxembourg, Centre Léon Bérard, France. The trial will validate the SIMS algorithm for matching patients.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
WIN Consortium in cancer personalized medicine has 2 employees across 1 departments.
Departments
Number of employees
Funding Data
WIN Consortium in cancer personalized medicine has never raised funding before.
WIN Consortium in cancer personalized medicine Tech Stack
Discover the technologies and tools that power WIN Consortium in cancer personalized medicine's digital infrastructure, from frameworks to analytics platforms.
CDN
PaaS
Web frameworks
JavaScript libraries
CMS
Reverse proxies
JavaScript libraries
Programming languages
Security
Video players
CDN
SSL/TLS certificate authorities
United States
Canada
Frequently asked questions
4.8
40,000 users
